STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Wellington Reports 7.17% Passive Position in Apellis Pharmaceuticals (APLS)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Wellington Management and affiliated entities report beneficial ownership of 9,009,522 shares of Apellis Pharmaceuticals common stock, equal to 7.17% of the class. The cover pages show no sole voting or dispositive power; voting power is shared for 8,713,716 shares and shared dispositive power for 9,009,522 shares, indicating these shares are held on behalf of clients of Wellington’s investment advisers. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control. Reporting persons include four Wellington entities classified as holding companies (HC) and an investment adviser (IA) where noted.

Positive

  • Material institutional holding: Wellington reports 9,009,522 shares (7.17%), a meaningful stake reflecting institutional interest.
  • Transparent structure: Filing identifies reporting entities and clarifies shares are held for clients through Wellington’s investment advisers.

Negative

  • No sole voting or dispositive power: Reporting persons indicate 0 sole voting and 0 sole dispositive power, limiting direct control influence.
  • Passive posture declared: Filing explicitly states holdings are not intended to change or influence issuer control, reducing near-term governance impact.

Insights

TL;DR A 7.17% institutional stake shows material passive interest but no direct control.

Wellington's aggregated 9.01M-share position is large enough to matter to investors as an indicator of institutional conviction. The filing reports zero sole voting or dispositive power, so the position appears passive and managed for clients rather than intended to influence corporate control. For market impact, this is disclosure of sizeable ownership rather than an active governance move.

TL;DR Significant share ownership disclosed, but structure and certifications signal non-activist posture.

The Schedule 13G lists multiple Wellington entities and classifies several as holding companies (HC) and at least one as an investment adviser (IA). The certification that the shares are held in the ordinary course and not to influence control, plus the absence of sole voting power, implies limited immediate governance pressure from this holder. This is material ownership information but not a change in control dynamics.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Management Company LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025

FAQ

How many Apellis (APLS) shares does Wellington beneficially own?

Wellington reports beneficial ownership of 9,009,522 shares of Apellis common stock.

What percentage of Apellis does Wellington own?

The reported position represents 7.17% of Apellis' outstanding common stock.

Does Wellington have sole voting or dispositive power over these Apellis shares?

No. The filing shows 0 sole voting power and 0 sole dispositive power; voting and disposition are reported as shared.

Are these shares held to influence control of Apellis?

The Schedule 13G certification states the securities are held in the ordinary course of business and not to change or influence control.

Which Wellington entities filed the Schedule 13G for APLS?

The filing lists four reporting persons: Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP.
Apellis Pharmace

NASDAQ:APLS

APLS Rankings

APLS Latest News

APLS Latest SEC Filings

APLS Stock Data

2.61B
106.61M
13.68%
105.74%
16.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM